HK1048941B - 具有治疗学有用性质的吲哚基-3-乙醛酸衍生物 - Google Patents

具有治疗学有用性质的吲哚基-3-乙醛酸衍生物 Download PDF

Info

Publication number
HK1048941B
HK1048941B HK03101178.9A HK03101178A HK1048941B HK 1048941 B HK1048941 B HK 1048941B HK 03101178 A HK03101178 A HK 03101178A HK 1048941 B HK1048941 B HK 1048941B
Authority
HK
Hong Kong
Prior art keywords
glyoxylamide
indol
pyridin
use according
acid addition
Prior art date
Application number
HK03101178.9A
Other languages
English (en)
Chinese (zh)
Other versions
HK1048941A1 (en
Inventor
B‧尼克尔
B‧尼克爾
T‧克伦尼尔
G‧巴彻尔
T‧克倫尼爾
T‧拜克尔斯
P‧艾米格
G‧巴徹爾
J‧恩格尔
E‧布鲁尼尔
T‧拜克爾斯
G‧卡姆
K‧皮特斯
J‧恩格爾
E‧布魯尼爾
Original Assignee
巴克斯特保健股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946301A external-priority patent/DE19946301A1/de
Application filed by 巴克斯特保健股份有限公司 filed Critical 巴克斯特保健股份有限公司
Publication of HK1048941A1 publication Critical patent/HK1048941A1/xx
Publication of HK1048941B publication Critical patent/HK1048941B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK03101178.9A 1999-09-28 2000-09-26 具有治疗学有用性质的吲哚基-3-乙醛酸衍生物 HK1048941B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19946301A DE19946301A1 (de) 1998-04-02 1999-09-28 Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE19946301.8 1999-09-28
PCT/EP2000/009390 WO2001022954A2 (de) 1999-09-28 2000-09-26 Indolyl-3-glyoxylsäurederivate als antitumormittel

Publications (2)

Publication Number Publication Date
HK1048941A1 HK1048941A1 (en) 2003-04-25
HK1048941B true HK1048941B (zh) 2007-09-21

Family

ID=7923485

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101178.9A HK1048941B (zh) 1999-09-28 2000-09-26 具有治疗学有用性质的吲哚基-3-乙醛酸衍生物

Country Status (32)

Country Link
EP (1) EP1218006B1 (cs)
JP (1) JP2003510274A (cs)
KR (1) KR100759242B1 (cs)
CN (1) CN1301712C (cs)
AR (1) AR025885A1 (cs)
AT (1) ATE459356T1 (cs)
AU (1) AU783436B2 (cs)
BG (1) BG106639A (cs)
BR (1) BR0014378A (cs)
CA (1) CA2386069C (cs)
CZ (1) CZ303246B6 (cs)
DE (1) DE50015879D1 (cs)
DZ (1) DZ3196A1 (cs)
EE (1) EE200200169A (cs)
ES (1) ES2342042T3 (cs)
GE (1) GEP20043250B (cs)
HK (1) HK1048941B (cs)
HR (1) HRP20020369A2 (cs)
HU (1) HUP0202788A3 (cs)
IL (2) IL148670A0 (cs)
IS (1) IS6319A (cs)
MX (1) MXPA02002824A (cs)
NO (1) NO322614B1 (cs)
NZ (1) NZ517988A (cs)
PL (1) PL199576B1 (cs)
RS (1) RS51302B (cs)
RU (1) RU2282444C2 (cs)
SK (1) SK287533B6 (cs)
TW (1) TWI269654B (cs)
UA (1) UA75872C2 (cs)
WO (1) WO2001022954A2 (cs)
ZA (1) ZA200202556B (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
MXPA05013121A (es) * 2003-06-05 2006-03-17 Zentaris Gmbh Derivados de indol con efecto de induccion de apoptosis.
EP1484329A1 (de) * 2003-06-06 2004-12-08 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
EP1595878A1 (de) * 2004-05-15 2005-11-16 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
CA2567813C (en) * 2004-05-23 2015-11-24 Gerard M. Housey Theramutein modulators
EP1809279B1 (en) * 2004-11-08 2013-05-29 Baxter International Inc. Particulate compositions of tubulin inhibitor
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US9040558B2 (en) 2004-12-31 2015-05-26 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
CA2670778A1 (en) * 2006-11-28 2008-06-05 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
WO2013024358A2 (en) 2011-08-18 2013-02-21 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
KR101803866B1 (ko) 2011-09-27 2017-12-04 닥터 레디스 레보러터리즈 리미티드 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN109111501B (zh) * 2017-06-23 2022-04-22 首都医科大学 脂肪氨基酸修饰的吲哚乙醇衍生物, 其合成，活性和应用
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
RU2047603C1 (ru) * 1991-12-09 1995-11-10 Матвей Абрамович Рехтер 1-алкил-2-ацилиндолы и способы их получения
NZ314207A (en) * 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
EP0617961A4 (en) * 1992-10-20 1995-03-29 Toray Industries INHIBITOR OF EOSINOPHILIN INFILTRATION.
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
CA2286038A1 (en) 1997-04-08 1998-10-15 Banyu Pharmaceutical Co., Ltd. Cancerous metastasis-associated gene
EA003876B1 (ru) * 1998-02-25 2003-10-30 Дженетикс Инститьют, Ллс Ингибиторы фосфолипазных ферментов
HUP0102612A2 (hu) * 1998-03-12 2001-11-28 Novo Nordisk A/S Fehérje-tirozinfoszfatázokat moduláló vegyületek és ezeket tartalmazó gyógyászati készítmények
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
UA59443C2 (uk) * 1998-04-28 2003-09-15 Арцнайміттельверк Дрезден Гмбх Гідроксііндол, спосіб його одержання, лікарська форма на його основі та спосіб її одержання
JP2000239252A (ja) * 1999-02-16 2000-09-05 Mitsubishi Chemicals Corp インドール誘導体
AU4834200A (en) * 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof

Also Published As

Publication number Publication date
BG106639A (bg) 2002-12-29
ATE459356T1 (de) 2010-03-15
HUP0202788A3 (en) 2003-02-28
WO2001022954A3 (de) 2002-03-28
CZ303246B6 (cs) 2012-06-20
YU22702A (sh) 2004-12-31
EP1218006A2 (de) 2002-07-03
SK4072002A3 (en) 2003-11-04
NO20021367L (no) 2002-05-22
PL199576B1 (pl) 2008-10-31
EE200200169A (et) 2003-04-15
NO322614B1 (no) 2006-11-06
CN1301712C (zh) 2007-02-28
IS6319A (is) 2002-03-21
KR20030019295A (ko) 2003-03-06
AU783436B2 (en) 2005-10-27
DE50015879D1 (de) 2010-04-15
HK1048941A1 (en) 2003-04-25
UA75872C2 (en) 2006-06-15
EP1218006B1 (de) 2010-03-03
AU7782900A (en) 2001-04-30
ES2342042T3 (es) 2010-07-01
MXPA02002824A (es) 2003-07-21
PL364811A1 (en) 2004-12-13
GEP20043250B (en) 2004-06-25
KR100759242B1 (ko) 2007-09-18
HRP20020369A2 (en) 2004-12-31
RS51302B (sr) 2010-12-31
RU2282444C2 (ru) 2006-08-27
IL148670A0 (en) 2002-09-12
WO2001022954A2 (de) 2001-04-05
JP2003510274A (ja) 2003-03-18
ZA200202556B (en) 2003-08-27
TWI269654B (en) 2007-01-01
DZ3196A1 (fr) 2001-04-05
SK287533B6 (sk) 2011-01-04
IL148670A (en) 2009-09-01
CN1376064A (zh) 2002-10-23
HUP0202788A2 (hu) 2003-01-28
AR025885A1 (es) 2002-12-18
CA2386069C (en) 2012-08-14
CA2386069A1 (en) 2001-04-05
CZ20021005A3 (cs) 2004-01-14
NZ517988A (en) 2004-10-29
NO20021367D0 (no) 2002-03-19
BR0014378A (pt) 2003-07-29

Similar Documents

Publication Publication Date Title
CN1301712C (zh) 具有治疗学有用性质的吲哚基－3－乙醛酸衍生物
US20080057124A1 (en) Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties
TWI399206B (zh) 抗腫瘤劑
WO2003074045A1 (fr) Agent antitumoral comprenant une combinaison d'un compose heterocyclique contenant un sulfamide et d'un inhibiteur d'angiogenese
TW200845983A (en) Methods of treating or preventing emesis using growth hormone secretagogues
JP2009517403A (ja) Ｐａｒｐ−１阻害剤の使用
JP5547487B2 (ja) 抗癌化合物の投与方法
US20100087398A1 (en) Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
JP4362457B2 (ja) 神経因性疼痛治療剤
CN1617744A (zh) 包含取代的丙烯酰偏端霉素衍生物和蛋白激酶(丝氨酸/苏氨酸激酶)抑制剂的抗肿瘤联合疗法
CN116850187A (zh) Hapalindole在制备抑制肝癌或乳腺癌的药物中的应用
CN1391484A (zh) 增强化疗疗效及治疗实体瘤的方法
WO2008031358A1 (fr) 1,2-dihydroxy-3-methyl-9,10-anthraquinone utile dans la fabrication de médicaments pour traiter les cancers
TW201012467A (en) Antitumor agent containing 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid
WO2009104150A1 (en) Combination comprising bosentan for treating ovarian cancer
HK1173090A (en) Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140926